Chinese biotech valuations likely hit as trailblazer’s Hong Kong shares sink

By
Posted

At least 10 more mostly Chinese biotechs plan to go public in the city this year, with some even dropping plans for U.S. share sales in favour of listing closer to home

Amata Holding raising up to $6.4m via OTC share sale, eyes Yangon listing

By

The proceeds will be used to develop five budget hotels under the brand, Awinka, over the next two years.


US private equity firm plans IPO of $732m Coronado Coal in Australia

By

The initial public offering is expected to value the whole company at around A$3 billion.


China’s Meituan Dianping said to draw Tencent as cornerstone investor for $4b IPO

By

Chinese social media giant Tencent Holdings Ltd already owns about a fifth of Meituan.


Saudi king puts a halt to Aramco IPO plans

By

The planned listing was to be the cornerstone of the kingdom’s promised economic overhaul and, at a targeted $100 billion, the biggest IPO ever.


Bitcoin mining equipment makers optimistic about raising ‘billions’ in HK IPO

By

Canaan and Ebang filed plans for floats in Hong Kong, while Bitmain is expected to file its plans next month to raise at least $3 billion


SGX partners Third500 to court US late-stage, venture-backed listings

By

SGX is partnering Third500 to court US venture-backed companies looking to list in Singapore.


Casino firm Landing’s shares slump after Chairman drops out of contact

By

The announcement comes just weeks after Landing’s $1.5 billion integrated casino project in the Philippines was halted by the president.


Elon Musk hires Morgan Stanley to evaluate on taking Tesla private

By

Morgan Stanley is advising Musk, not the company, its board or a special board committee formed to evaluate a potential take-private proposal


Chinese biopharma firm Mabpharm files for Hong Kong IPO

By

Mabpharm is the second biotech firm to file to list in Hong Kong this week after Suzhou-based Ascentage Pharma Group.